Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

2.

Hospital variation and characteristics of implantable cardioverter-defibrillator use in patients with heart failure: data from the GWTG-HF (Get With The Guidelines-Heart Failure) registry.

Shah B, Hernandez AF, Liang L, Al-Khatib SM, Yancy CW, Fonarow GC, Peterson ED; Get With The Guidelines Steering Committee..

J Am Coll Cardiol. 2009 Feb 3;53(5):416-22. doi: 10.1016/j.jacc.2008.09.045.

3.
4.

Dual-chamber implantable cardioverter-defibrillator selection is associated with increased complication rates and mortality among patients enrolled in the NCDR implantable cardioverter-defibrillator registry.

Dewland TA, Pellegrini CN, Wang Y, Marcus GM, Keung E, Varosy PD.

J Am Coll Cardiol. 2011 Aug 30;58(10):1007-13. doi: 10.1016/j.jacc.2011.04.039.

5.
6.

Prevalence, correlates, and temporal trends in antiarrhythmic drug use at discharge after implantable cardioverter defibrillator placement (from the National Cardiovascular Data Registry [NCDR]).

Dev S, Peterson PN, Wang Y, Curtis JP, Varosy PD, Masoudi FA.

Am J Cardiol. 2014 Jan 15;113(2):314-20. doi: 10.1016/j.amjcard.2013.09.023.

PMID:
24216126
7.
8.

Evaluation oF FactORs ImpacTing CLinical Outcome and Cost EffectiveneSS of the S-ICD: design and rationale of the EFFORTLESS S-ICD Registry.

Pedersen SS, Lambiase P, Boersma LV, Murgatroyd F, Johansen JB, Reeve H, Stuart AG, Adragao P, Theuns DA.

Pacing Clin Electrophysiol. 2012 May;35(5):574-9. doi: 10.1111/j.1540-8159.2012.03337.x.

PMID:
22360677
9.

Variation in use of dual-chamber implantable cardioverter-defibrillators: results from the national cardiovascular data registry.

Matlock DD, Peterson PN, Wang Y, Curtis JP, Reynolds MR, Varosy PD, Masoudi FA.

Arch Intern Med. 2012 Apr 23;172(8):634-41; discussion 641. doi: 10.1001/archinternmed.2012.394.

PMID:
22529229
10.

Use of remote monitoring of newly implanted cardioverter-defibrillators: insights from the patient related determinants of ICD remote monitoring (PREDICT RM) study.

Akar JG, Bao H, Jones P, Wang Y, Chaudhry SI, Varosy P, Masoudi FA, Stein K, Saxon LA, Curtis JP.

Circulation. 2013 Nov 26;128(22):2372-83. doi: 10.1161/CIRCULATIONAHA.113.002481.

11.

Effect of risk stratification on cost-effectiveness of the implantable cardioverter defibrillator.

Owens DK, Sanders GD, Heidenreich PA, McDonald KM, Hlatky MA.

Am Heart J. 2002 Sep;144(3):440-8.

PMID:
12228780
12.

Impact of a recent lead recall on utilization of implantable cardioverter defibrillators: data from the NCDR ICD Registry™.

Bhatt P, Curtis J, Wang Y, Lampert R.

J Cardiovasc Electrophysiol. 2012 Aug;23(8):861-5. doi: 10.1111/j.1540-8167.2012.02310.x.

PMID:
22452744
13.

Characteristics and outcomes of patients receiving new and replacement implantable cardioverter-defibrillators: results from the NCDR.

Kramer DB, Kennedy KF, Noseworthy PA, Buxton AE, Josephson ME, Normand SL, Spertus JA, Zimetbaum PJ, Reynolds MR, Mitchell SL.

Circ Cardiovasc Qual Outcomes. 2013 Jul;6(4):488-97. doi: 10.1161/CIRCOUTCOMES.111.000054.

14.

Use of implantable cardioverter defibrillators for primary prevention in the community: do women and men equally meet trial enrollment criteria?

Daugherty SL, Peterson PN, Wang Y, Curtis JP, Heidenreich PA, Lindenfeld J, Vidaillet HJ, Masoudi FA; NCDR..

Am Heart J. 2009 Aug;158(2):224-9. doi: 10.1016/j.ahj.2009.05.018.

PMID:
19619698
15.

The Italian Implantable Cardioverter-Defibrillator Registry. A survey of the national activity during the years 2001-2003.

Proclemer A, Ghidina M, Cicuttini G, Gregori D, Fioretti PM.

Ital Heart J. 2005 Mar;6(3):272-80.

PMID:
15875520
16.

Racial disparity in the utilization of implantable-cardioverter defibrillators among patients with prior myocardial infarction and an ejection fraction of <or=35%.

Thomas KL, Al-Khatib SM, Kelsey RC 2nd, Bush H, Brosius L, Velazquez EJ, Peterson ED, Gilliam FR.

Am J Cardiol. 2007 Sep 15;100(6):924-9.

PMID:
17826371
17.

Cost effectiveness of the implantable cardioverter defibrillator: a preliminary analysis.

O'Brien BJ, Buxton MJ, Rushby JA.

Br Heart J. 1992 Aug;68(2):241-5.

18.

Cost-benefit analysis of primary prevention of sudden cardiac death with an implantable cardioverter defibrillator versus amiodarone in Canada.

Deniz HB, Ward A, Jaime Caro J, Alvarez P, Sadri H.

Curr Med Res Opin. 2009 Mar;25(3):617-26. doi: 10.1185/03007990802695037 .

PMID:
19232036
19.

Developing a risk model for in-hospital adverse events following implantable cardioverter-defibrillator implantation: a report from the NCDR (National Cardiovascular Data Registry).

Dodson JA, Reynolds MR, Bao H, Al-Khatib SM, Peterson ED, Kremers MS, Mirro MJ, Curtis JP; NCDR..

J Am Coll Cardiol. 2014 Mar 4;63(8):788-96. doi: 10.1016/j.jacc.2013.09.079.

20.

Physician procedure volume and complications of cardioverter-defibrillator implantation.

Freeman JV, Wang Y, Curtis JP, Heidenreich PA, Hlatky MA.

Circulation. 2012 Jan 3;125(1):57-64. doi: 10.1161/CIRCULATIONAHA.111.046995.

Items per page

Supplemental Content

Support Center